At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 406 enrolled
Drug / intervention
Placebo (placebo matching AZD5004 film-coated tablet) +2 moredrug
Likely dose
Semaglutide 14 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb, Randomized, Double-blind, Placebo-controlled and Open-label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults With Type 2 Diabetes Mellitus.
In Brief
A Phase 2 clinical trial evaluating Placebo (placebo matching AZD5004 film-coated tablet), AZD5004, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 406 participants across 97 sites in 9 countries.
Detailed Summary
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesCanada, Germany, Hungary, Japan, Poland, Slovakia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20252026
First PostedAug 2024
Enrollment StartOct 2024
Primary CompletionDec 2025
TodayJul 2026
First PostedAug 30, 2024
Enrollment StartOct 8, 2024
Primary CompletionDec 19, 2025
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 1.8 years ago
Interventions
Placebo (placebo matching AZD5004 film-coated tablet)drug
Placebo film-coated tablet (matching AZD5004)
AZD5004drug
AZD5004 film-coated tablet, once daily during 26 weeks
Semaglutidedrug
3-14 mg tablets of Semaglutide